Teva Pharmaceutical Industries Ltd. has launched AirDuo RespiClick, an inhalation powder for the treatment of asthma in patients 12 and older.
The medication is meant for the treatment of those suffering from asthma and are not controlled on inhaled corticosteroid (ICS), or those who require the use of ICS/long-acting beta-adrenergic agonist combination.
"With the launch of AirDuo RespiClick and its authorized generic, our intent is to meet the needs of patients, providers, and payers in the U.S. seeking greater access to lower-cost asthma inhaler technology, while also allowing Teva to compete in the highly competitive asthma combination controller market," Rob Koremans, president and CEO of Global Specialty Medicines at Teva, said.
AirDuo RespiClick was approved by the FDA in January in three dosage options: 55/14 mcg, 113/14 mcg and 232/14 mcg, to be given as one dose twice a day.
Alerts Sign-up